Recently, the Sichuan Provincial Department of Economy and Information Technology officially announced the list of companies recognized as "Advanced Intelligent Factories" in Sichuan Province for 2026. As a core force in China's blood products industry, Grand Shuyang, having previously received municipal-level honors for intelligent manufacturing in Chengdu, successfully passed the rigorous provincial evaluation and was listed, owing to its systematic layout and solid achievements in digital transformation and intelligent upgrading. This recognition not only marks Grand Shuyang's leap in intelligent manufacturing capability—from a "municipal-level benchmark" to a "provincially advanced level"—but also signifies that the Company has become an "intelligent manufacturing exemplar" in the high-quality development of Sichuan's pharmaceutical industry.

Establishing a Full-Chain Intelligent Manufacturing Defense Guided by "Quality Is Life"

As a core force in China's blood products industry, Grand Shuyang has ingrained the quality management philosophy of "one dose and two lives" into its corporate DNA. The provincial-level intelligent factory designation originates from the Company's long-term strategic layout of an intelligent system covering the entire business chain.

By deeply integrating core systems such as MES (Manufacturing Execution System), SCADA (Supervisory Control and Data Acquisition), and LIMS (Laboratory Information Management System), the Company has achieved end-to-end data integration and real-time controllability throughout the process from plasma warehousing to warehouse-out of finished products. Every batch of products can be precisely traced, creating a solid intelligent manufacturing safeguard for medication safety from source to destination.

Safeguarding "Healthy China" Through Intelligent Manufacturing

Honors are milestones and they serve as clarion calls for new journeys. Anchored in the "15th Five-Year Plan" strategy for building a manufacturing powerhouse, Grand Shuyang will capitalize on this recognition as an opportunity to accelerate the transformation of the blood products industry from "manufacturing" to "intelligent manufacturing".

Looking ahead, Grand Shuyang will continue to deepen the integration and innovation of artificial intelligence and biomanufacturing, fully leverage its role as an intelligent manufacturing benchmark, build an intelligent manufacturing safeguard to protect public health through new quality productive forces, thus contributing robust Shuyang strength to the "Healthy China" initiative and the high-quality development of China's manufacturing industry.